Show simple item record

dc.contributor.authorFornaro, Michele
dc.contributor.authorDe Berardis, Domenico
dc.contributor.authorPerna, Giampaolo
dc.contributor.authorSolmi, Marco
dc.contributor.authorVeronese, Nicola
dc.contributor.authorOrsolini, Laura
dc.contributor.authorBuonaguro, Elisabetta Filomena
dc.contributor.authorIasevoli, Felice
dc.contributor.authorKöhler, Cristiano André
dc.contributor.authorCarvalho, André Ferrer
dc.contributor.authorDe Bartolomeis, Andrea
dc.date.accessioned2017-07-25T16:29:53Z
dc.date.available2017-07-25T16:29:53Z
dc.date.issued2017-05-09
dc.identifier.citationFornaro , M , De Berardis , D , Perna , G , Solmi , M , Veronese , N , Orsolini , L , Buonaguro , E F , Iasevoli , F , Köhler , C A , Carvalho , A F & De Bartolomeis , A 2017 , ' Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews ' , BioMed Research International , vol. 2017 , 3084859 . https://doi.org/10.1155/2017/3084859
dc.identifier.issn2314-6133
dc.identifier.otherPURE: 12009643
dc.identifier.otherPURE UUID: b1caf9cf-06b5-47e4-8e53-0b7200d6e277
dc.identifier.otherScopus: 85019547479
dc.identifier.urihttp://hdl.handle.net/2299/19092
dc.descriptionCopyright © 2017 Michele Fornaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.description.abstractIntroduction. A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic. Methods. Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception until October 2016. Results. Twelve included systematic reviews were of moderate-to-high quality and consistent in covering the handful of RCTs available to date, suggesting the promising efficacy, safety, and tolerability profile of lurasidone. Concordance on the drug profile seems to be corroborated by a steadily increasing number of convergent qualitative reports on the matter. Limitations. Publication, sponsorship, language, citation, and measurement biases. Conclusions. Despite being preliminary in nature, this overview stipulates the effectiveness of lurasidone in the acute treatment of Type I bipolar depression overall. As outlined by most of the reviewed evidence, recommendations for future research should include further controlled trials of extended duration.en
dc.format.extent17
dc.language.isoeng
dc.relation.ispartofBioMed Research International
dc.subjectImmunology and Microbiology(all)
dc.subjectBiochemistry, Genetics and Molecular Biology(all)
dc.titleLurasidone in the Treatment of Bipolar Depression: : Systematic Review of Systematic Reviewsen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionUniversity of Hertfordshire
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85019547479&partnerID=8YFLogxK
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1155/2017/3084859
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record